Related Experiment Video
Updated: Mar 16, 2026
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
Relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients
Qing Qin1, Juying Qian, Jianying Ma
1Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Disease, Shanghai, China..
Insights
Serum endostatin levels are higher in patients with poor coronary collateral development. Lower endostatin is linked to better collateral growth, suggesting it as a biomarker and therapeutic target for coronary artery disease.
Area of Science:
- Cardiology
- Vascular Biology
- Biomarkers
Background:
- Coronary collateral vessel (CCV) development is crucial for patients with chronic total occlusions (CTO).
- Angiostatic and angiogenic factors' roles in CCV formation are not fully understood.
- Identifying biomarkers for CCV development can guide therapeutic strategies.
Purpose of the Study:
- To investigate the association between serum angiostatic factors (thrombospondin-1 [TSP-1], endostatin) and angiogenic factors (angiopoietin-2 [Ang-2]) with CCV development in CTO patients.
- To determine if these factors can serve as biomarkers for CCV formation.
Main Methods:
- Serum levels of TSP-1, endostatin, and Ang-2 were measured in 149 patients with CTO and 39 controls.
- Patients with CTO were categorized into good (Rentrop grades 2-3) and poor (Rentrop grades 0-1) collateral groups.
- Multivariate analysis was used to identify independent predictors of CCV development.
Main Results:
- Serum endostatin levels were significantly higher in the poor collateral group compared to both control and good collateral groups.
- Decreased serum endostatin levels were independently associated with good CCV development.
- Serum TSP-1 levels were lower in CTO patients than controls, but not different between collateral groups.
- Serum Ang-2 levels showed no significant difference among the groups.
Conclusions:
- Circulatory endostatin may be a valuable biomarker for assessing coronary collateral development in CTO patients.
- Endostatin presents a potential therapeutic target for promoting angiogenesis in CTO.
- Further research is warranted to explore endostatin's role in therapeutic angiogenesis.
Abstract:
This study is aimed to investigate whether serum angiostatic factors (thrombospondin-1 [TSP-1] and endostatin) or angiogenic factors (angiopoietin-2 [Ang-2]) are related to coronary collateral vessel development in patients with chronic total occlusion (CTO).A total of 149 patients were enrolled in the study, and 39 patients with coronary artery disease but without significant stenosis were included in control group. In 110 patients with CTO lesion, 79 with Rentrop grades 2 to 3 collaterals were grouped as good collateral, while 31 with Rentrop grades 0 to 1 collaterals were grouped as poor collateral. Serum TSP-1, endostatin, and Ang-2 levels were studied.Serum endostatin level was significantly higher in poor collateral group compared with control group and good collateral group, respectively (96.2 ± 30.4 vs 77.8 ± 16.5 ng/mL, P = 0.007; 96.2 ± 30.4 vs 81.2 ± 30.4 ng/mL, P = 0.018). In multivariate analysis, decreased serum endostatin level was independently related to good coronary collateral development. Serum TSP-1 level was lower in patients with CTO compared with control group. However, no difference in TSP-1 level was detected between poor and good collateral group. The serum Ang-2 level did not show a significant difference among 3 groups.Circulatory endostatin may be a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis in patients with CTO.
Related Concept Videos
01:26Coronary Artery Disease II: Pathophysiology
01:24Regulation of Angiogenesis and Blood Supply